Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MediPharm Labs (TSE:LABS)
TSX:LABS
Holding TSE:LABS?
Track your performance easily
LABS Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.06 - C$0.10
Previous CloseC$0.07
Volume180.15K
Average Volume (3M)224.78K
Market Cap
C$26.72M
Enterprise ValueC$13.54M
Total Cash (Recent Filing)C$15.99M
Total Debt (Recent Filing)C$2.81M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Mar 26, 2025EPS Estimate
C$0Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding404,048,948
10 Day Avg. Volume330,253
30 Day Avg. Volume224,777
Standard Deviation0.16
R-Squared0.07
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)0.70
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
MediPharm Labs News
PremiumCompany Announcements
MediPharm Labs Sells Facility, Partners with Kensana
PremiumCompany Announcements
MediPharm Labs Reports Strong Q3 Growth
PremiumCompany Announcements
MediPharm Labs Reports Financial Growth and Expansion
PremiumCompany Announcements
MediPharm Labs Shows Strong Q3 GrowthPremiumCompany Announcements
MediPharm Labs to Announce Q3 2024 Results
Options Prices
Currently, No data available
---
Ownership Overview
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
Currently, no data Available
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Nov 14, 2024. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of -C$0.003 by -C$0.007.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is C$0.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 411,120,270 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of -C$0.01 in its last earnings report, missing expectations of -C$0.003. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
---
MediPharm Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.41%
12-Months-Change
Fundamentals
Return on Equity
-23.66%
Trailing 12-Months
Asset Growth
-17.82%
Trailing 12-Months
Company Description
MediPharm Labs
MediPharm Labs Corp has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulation without first receiving a cannabis cultivation license. The focus on cannabis concentrates from current Good Manufacturing Practices and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for derivative products. The company has invested in research-driven team, technology, downstream extraction methodologies and purpose-built facilities to deliver safe and precisely-dosed cannabis products to patients and consumers.
---
LABS Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook, with significant progress towards profitability and strong international sales growth, particularly in Germany and Australia. The company also highlighted a strong balance sheet with minimal debt. However, challenges remain in the Canadian market and the broader cannabis industry, impacting overall sentiment.Read More>---
Technical Analysis
Auxly Cannabis Group
―
Cronos Group
―
Canopy Growth
―
Aurora Cannabis
―
MediPharm Labs
―
---